Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Prognostic marker profile to assess risk in stage I-III hormone receptor-positive breast cancer patients.

Bremer TM, Jacquemier J, Charafe-Jauffret E, Viens P, Birnbaum D, Linke SP.

Int J Cancer. 2009 Feb 15;124(4):896-904. doi: 10.1002/ijc.24001.

2.

A multimarker model to predict outcome in tamoxifen-treated breast cancer patients.

Linke SP, Bremer TM, Herold CD, Sauter G, Diamond C.

Clin Cancer Res. 2006 Feb 15;12(4):1175-83.

3.

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.

Spector NL, Xia W, Burris H 3rd, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S.

J Clin Oncol. 2005 Apr 10;23(11):2502-12. Epub 2005 Jan 31.

PMID:
15684311
4.

Frequency characterization of blood glucose dynamics.

Gough DA, Kreutz-Delgado K, Bremer TM.

Ann Biomed Eng. 2003 Jan;31(1):91-7. Review.

PMID:
12572659
5.

Benchmark data from the literature for evaluation of new glucose sensing technologies.

Bremer TM, Edelman SV, Gough DA.

Diabetes Technol Ther. 2001 Fall;3(3):409-18.

PMID:
11762520

Supplemental Content

Loading ...
Support Center